Dr Palace is Consultant Neurologist in Oxford and runs the regional MS service and General neurology for the Banbury area.
She is Lead for the national Congenital Myasthenia service and also runs a joint National Neuromyelitis Service with the Walton Centre Liverpool.
She is a clinical lead for the UK MS risk sharing scheme study assessing the long term effects of beta-interferon and Copaxone.
On Oct 2011 she has published over 80 papers and reviews.
Awards Training and Qualifications
- 1983 BM Honours and Clinical Distinction, SOTON
- 1986 MRCP, SOTON
- 1992 DM, SOTON
- 1995 Accredited Neurology
- 2000 FRCP
BM (Hons) FRCP DM
- Oxford Multiple Sclerosis and Neuromyelitis Group
Neuromyelitus optica, multiple sclerosis and myasthenia
Dr. Palace leads the Oxford Multiple Sclerosis and Neuromyelitis Group. This comprises a regional clinical service and a clinical research group. Research topics include clinical treatment trials, immunological studies, biomarkers and imaging studies on neurodegeneration and its detection and association with inflammation. The group welcomes referrals of patients.
Sources of Funding
The influence of HLA-DRB1*15 on the relationship between microglia and neurons in multiple sclerosis normal appearing cortical grey matter.
Yates RL. et al, (2021), Brain Pathol
Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V. et al, (2021), JAMA Netw Open, 4
Retinal Optical Coherence Tomography in Neuromyelitis Optica.
Oertel FC. et al, (2021), Neurol Neuroimmunol Neuroinflamm, 8
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders.
Lu A. et al, (2021), J Neurol Neurosurg Psychiatry
Increasing role of imaging in differentiating MS from non-MS and defining indeterminate borderline cases.
Juryńczyk M. et al, (2021), Neurol Neurochir Pol